KLRS
Kalaris Therapeutics, Inc.
2.50$
-2.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -5.3% | +5.6% | -5.3% | +0.0% | +0.0% | +83.3% | +33.3% | +1,159.1% | +52.7% | -49.6% | -53.3% | +449.7% | -50.0% | – | – | – | – | – | – | – | – | – | – | – | +0.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +139.4% | +105.3% | +17.9% | +2.3% | +30.0% | +93.6% | -2.5% | +21.7% | +25.9% | +28.8% | +24.3% | -31.3% | +9.7% | -3.7% | -8.3% | +10.4% | +15.4% | -12.4% | -90.3% | -33.9% | +63.7% | +1,021.8% | -99.1% | +1,784.4% | +40.0% | +8.1% | -21.6% | +5.8% | +19.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +20.9% | +62.1% | +87.4% | +79.5% | +31.7% | -11.7% | -5.3% | +0.8% | +16.9% | -21.0% | – | |
| – | +102.3% | +42.6% | +11.9% | +3.5% | +23.5% | +96.8% | +6.3% | +21.4% | +22.0% | +20.8% | +21.5% | -23.3% | +4.4% | -3.3% | -8.0% | +8.5% | +10.8% | -8.4% | -92.0% | -26.0% | +63.4% | +804.0% | -48.4% | -47.0% | +18.4% | +4.0% | -15.3% | +9.6% | +4.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +100.0% | +539.7% | +63.3% | +60.6% | +10.2% | -100.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.